| The use of SGLT2i was associated with a lower rate of incident HF and prolonged overall survival in patients with cancer with diabetes mellitus (Heart Journal)
Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo (NEJM)
Based on current data, islet transplantation successfully reduces severe hypoglycemia and insulin requirement. However, graft survival is still not good enough, which leads to a low rate of insulin independence and an unsatisfactory long-term glycemic control (Journal of Diabetes Investigation)
In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure irrespective of diabetes status, primary kidney disease, or kidney function (The Lancet)
The COVID-19 pandemic exemplifies the collective effects of politics, economics, social factors, and technology on a pandemic, whereby acute infectious disease and chronic disease meet. Whether at the individual or the community level, acute infections such as COVID-19 and chronic diseases (eg, diabetes) are inexorably related. The response to them needs to be coordinated similarly (The Lancet Diabetes & Endocrinology)
Empagliflozin at 2.5 and 5 mg increased time in range during hybrid closed-loop therapy by 11–13 percentage points compared with placebo in those who otherwise were unable to attain glycemic targets. Future studies are required to assess long-term efficacy and safety (Diabetes Care)
Faricimab, a bi-specific antibody simultaneously directed against Ang2 and VEGF, has shown promising results in clinical trials among patients with diabetic retinopathy, and other agents targeting the angiopoietin system are currently in development (Diabetes Therapy)
| 
